Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue.
There is a growing interest in the exploitation of hypoxia in solid tumors for therapeutic gain by the use of hypoxic cytotoxins and other agents. Tumor hypoxia can be greatly increased in a number of animal tumor models with the vasoactive drug hydralazine (HDZ), and in some cases this potentiates the effect of drugs that are selectively toxic to hypoxic cells. Our interest was to determine if HDZ would also increase tumor hypoxia in tumors growing in previously irradiated normal tissue- a situation such as might be found in the clinic with regrowing solid tumors after radiotherapy. SCCVII tumors in untreated mice were compared with tumors growing in a previously irradiated tissue with respect to their level of hypoxia in response to HDZ. HDZ increased tumor hypoxia in the tumors from unirradiated mice as measured by 14C-misonidazole binding. However, HDZ had little or no effect on tumor hypoxia in tumors growing in previously irradiated sites. We also showed that the pre-HDZ extent of hypoxia was higher in tumors growing in a previously irradiated tissue. This may in part explain the lack of effect of HDZ in these tumors. The lack of response of the tumors growing in irradiated sites suggests a limitation on the use of HDZ in combination with specific hypoxic cytotoxins or other chemotherapeutic drugs in the treatment of recurrent solid tumors. The data also show that if such tumors have an elevated hypoxic fraction relative to their counterparts growing in untreated sites, these tumors might be intrinsically more resistant to conventional radiotherapy, but, on the other hand, might be sensitive to bioreductive drugs and more likely to be radiosensitized by a hypoxic cell sensitizer.
Department of Radiation Oncology, Stanford University School of Medicine, CA 94305.
M J
MJ
Lemmon
J M
JM
Brown
D000818:Animals; D002250:Carbon Radioisotopes / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D015687:Cell Hypoxia / Q000528:radiation effects*; D004334:Drug Administration Schedule; D005260:Female; D006830:Hydralazine / Q000494:pharmacology*; D051379:Mice; D008809:Mice, Inbred C3H; D008920:Misonidazole / Q000378:metabolism*; D009368:Neoplasm Transplantation; D011879:Radiotherapy Dosage
D002250:Carbon Radioisotopes; D006830:Hydralazine; D008920:Misonidazole